The PANAMA score effectively stratifies pancreatic cancer patients post-resection into low-, intermediate-, and high-risk categories, correlating with median overall survival rates of 48.5, 27.6, and 22.3 months, respectively. Adjuvant therapy demonstrated no survival benefit in low-risk patients, while significant improvements were seen in both intermediate (HR: 0.58) and high-risk groups (HR: 0.47). This validation underscores the score’s utility in guiding treatment decisions for patients following neoadjuvant FOLFIRINOX therapy.
Validation Study by Rompen IF, Stoop TF (…) Hank T et 42 al. in Ann Surg
Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.